Boehringer Ingelheim recently announced the results of the Phase III VIVACITO® study investigating the effect of tiotropium and olodaterol fixed-dose combination (T+O FDC) delivered by the Respimat inhaler to improve lung function in patients with chronic obstructive pulmonary disease (COPD). This data is the first of its kind posted from the ToviTO clinical trial program.
The TOviTO® Phase III clinical trial program is a global study involving more than 8,000 patients with COPD to investigate the efficacy and safety of tiotropium plus olodaterol FDC delivered by the Respimat® SoftMist™ inhaler. The TOviTO® program includes several clinical trials, including VIVACITO®, MORACTO® 1+2, TORRACTO®, ENERGITO®, PHYSACTO®, OTEMTO® 1+2 and TONADO® 1+2.
Tiotropium (Spiriva®) is a well-established, once-daily, long-acting muscarinic antagonist (LAMA) and olodaterol (Striverdi®) is the new once-daily long-acting beta agonist (LABA). The Respimat® SoftMist™ Inhaler is an innovative device which allows gentle inhalation, making it easy for patients to take their therapy.
In the Phase III VIVACITO® study with 219 patients with moderate to very severe COPD, researchers observed improvement in lung function with the combination use of tiotropium and olodaterol. “This is good news as we have learned that not all patients respond to just one therapy and more options are needed, particularly considering the incidence of COPD is projected to increase worldwide in the coming decades,” said Klaus F. Rabe, Professor of Pulmonary Medicine at the University of Kiel and Director of the Department of Pneumology at Clinic Grosshansdorf in Germany.
Results of the study were presented at the American Thoracic Society (ATS) 2014 International Conference.
For the details of the clinical study, visit: https://clinicaltrials.gov/ct2/show/NCT01431287?term=olodaterol&rank=5
For the details of the ATS 2014 International Conference, visit: http://conference.thoracic.org/2014/